Existing-Home Sales Dipped 2.5% in August
September 19, 2024 10:00 ET
|
National Association of Realtors®
Washington, D.C., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Key Highlights Existing-home sales retreated 2.5% in August to a seasonally adjusted annual rate of 3.86 million. Sales slid 4.2% from...
Final results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx® in advanced neuroendocrine tumors
September 16, 2024 08:45 ET
|
Ipsen Pharma
Data demonstrated statistically significant and clinically meaningful reduction in risk of disease progression or death with Cabometyx® (cabozantinib) versus placebo in advanced pancreatic and...
Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024
September 14, 2024 04:15 ET
|
Cullinan Therapeutics, Inc.
Updated data show consistent objective response rate of 40% and manageable safety profile in patients with non-small cell lung cancer harboring epidermal growth factor receptor exon 20 insertion...
Press Release: Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers
September 12, 2024 01:00 ET
|
Sanofi - Aventis Groupe
Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers Paris, France, and Houston, Texas, September 12, 2024....
Smith+Nephew brings pre-operative planning and accuracy to total ankle replacement with new TOTAL ANKLE Patient-Matched Guides
September 10, 2024 10:00 ET
|
Smith & Nephew UK Ltd
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the launch of its TOTAL ANKLE Patient-Matched Guides, giving surgeons a predictable and efficient option to help...
ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer
September 09, 2024 12:05 ET
|
ArriVent BioPharma, Inc.
81.8% ORR by BICR and 63.6% confirmed ORR by BICR at the 240 mg dose; 46.2% confirmed ORR in CNS Metastases 90.9% (n = 20/22) of patients with confirmed responses remained on study with a median...
Halberd Corp. Issues Letter to Shareholders - Patented LDN+ Evolves into WatchDawg™ for Veteran Suicide Reduction
September 09, 2024 09:31 ET
|
Halberd Corp.
Halberd Corp. Issues Letter to Shareholders - Patented LDN+ Evolves into WatchDawg™ for Veteran Suicide Reduction
Multiple Myeloma Market Report and Company Analysis, 2024-2032 Featuring Novartis, AbbVie., Sanofi, Johnson & Johnson, Baxter International, Pfizer, Takeda Pharmaceutical, and Bristol-Myers Squibb
September 04, 2024 10:06 ET
|
Research and Markets
Dublin, Sept. 04, 2024 (GLOBE NEWSWIRE) -- The "Multiple Myeloma Market Report, Forecast by Drugs Types, Disease Types, End User, Countries and Company Analysis, 2024-2032" report has been added to ...
World Personal Credit Cards Industry Research 2024: Unique Card Structures Reflect Market Realities, Americas and Asia Pacific Set the Pace
September 03, 2024 05:14 ET
|
Research and Markets
Dublin, Sept. 03, 2024 (GLOBE NEWSWIRE) -- The "Personal Credit Cards Around the World" report has been added to ResearchAndMarkets.com's offering.The Personal Credit Cards Around the World global...
At 13.1% CAGR, Rare Diseases Market Size Anticipated to Reach USD 547.5 Billion by 2030: Prophecy Market Insights
August 30, 2024 09:13 ET
|
PMI
Covina, Aug. 30, 2024 (GLOBE NEWSWIRE) -- According to Prophecy Market Insights, the global rare disease market size and share value is projected to grow from USD 161.4 Billion in 2020 and is...